Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in December

Coya Therapeutics, Inc. (NASDAQ:COYA) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily trading volume, of 92,500 shares, the short-interest ratio is presently 2.3 days.

Insider Activity at Coya Therapeutics

In other news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares of the company’s stock, valued at approximately $36,700. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought 9,510 shares of company stock valued at $69,615 in the last three months. Corporate insiders own 9.80% of the company’s stock.

Institutional Trading of Coya Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new position in Coya Therapeutics in the second quarter worth $101,000. GHP Investment Advisors Inc. bought a new stake in shares of Coya Therapeutics during the 3rd quarter worth $169,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA traded down $0.22 during trading on Monday, hitting $5.38. The stock had a trading volume of 63,988 shares, compared to its average volume of 51,707. The firm has a fifty day moving average of $6.02 and a two-hundred day moving average of $6.49. The company has a market capitalization of $89.90 million, a PE ratio of -8.28 and a beta of 0.46. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, equities analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on COYA shares. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday, December 18th. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.